Universitätsklinikum Dresden Medizinische Klinik und Poliklinik I
Welcome,         Profile    Billing    Logout  
 10 Trials 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Platzbecker, Uwe
TUD-APOLLO-064, NCT02688140 / 2015-001151-68: Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Active, not recruiting
3
280
Europe
Arsenic trioxide, ATO, Trisenox (R), As2O3, Idarubicin, IDA, Cytarabine, Ara-C, Tretinoin, all-trans retinoic acid, ATRA, Mitoxantrone, MTZ, Mercaptopurine, 6-Mercaptopurine, 6-MP, Methotrexate, MTX
Technische Universität Dresden, Gruppo Italiano Malattie EMatologiche dell'Adulto, Groupe Francophone des Myelodysplasies, HOVON - Dutch Haemato-Oncology Association, Programa para el Tratamiento de Hemopatías Malignas, German Federal Ministry of Education and Research, Teva Pharmaceuticals Europe
Acute Promyelocytic Leukemia
01/25
01/25
NCT04712942: Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

Completed
2
14
Europe
Pevonedistat, Azacitidine
University of Leipzig, Millennium Pharmaceuticals, Inc.
Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Minimal Residual Disease
01/23
01/23
PEMAZA, NCT03769532 / 2017-004110-25: MRD-guided Treatment in NPM1mut AML Patients

Recruiting
2
28
Europe
Pembrolizumab, PEM, Keytruda®, Azacitidine, AZA, Vidaza®
Technische Universität Dresden, Merck Sharp & Dohme LLC
Acute Myeloid Leukemia
12/25
12/26
IMpress, NCT05583552: Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

Active, not recruiting
2
46
Europe, RoW
Imetelstat sodium, GRN163L
GCP-Service International West GmbH, Geron Corporation, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, QIMR Berghofer Medical Research Institute, Australasian Leukaemia and Lymphoma Group, Groupe Francophone des Myelodysplasies, German Myelodysplastic Syndrome Study Group
Myelodysplastic Syndromes, Acute Myeloid Leukemia
02/25
06/26
LUCAS, NCT05178342: Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

Terminated
2
38
Europe
CA-4948, Emavusertib
University of Leipzig, Curis, Inc.
Myelodysplastic Syndromes, Anemia
07/24
07/24
REMARK_001, NCT06243458: RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

Recruiting
2
41
Europe
RVU120 (SEL120)
GCP-Service International West GmbH, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, University of Florence, University of Salamanca, Medical University of Warsaw, Ryvu Therapeutics SA, European Myelodysplastic Neoplasms Cooperative Group
Low Risk Myelodysplastic Syndromes
05/26
05/27
PALOMA, NCT04061239 / 2018-002430-21: Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML

Recruiting
2
150
Europe
CPX-351, Vyxeos, Daunorubicin, Cytarabine, Azacitidine, Vidaza
GWT-TUD GmbH
MDS, AML
03/26
09/26
MAGROLIC, NCT05829434: Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS

Withdrawn
2
108
NA
Magrolimab, Hu5F9-G4, GS-4721, 7+3, Daunorubicine and Cytarabine, CPX-351, Vyxeos®
Uwe Platzbecker, Gilead Sciences
Acute Myeloid Leukemia, Myelodysplastic Neoplasm
08/28
08/29
APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
240
Europe, US, RoW
Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax, Azacitidine for Intravenous Infusion, Azacitidine
Aptose Biosciences Inc.
Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia
11/26
04/27
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
AbbVie, Jazz Pharmaceuticals
Acute Myeloid Leukemia
04/26
04/26
CA-4948 102, NCT04278768 / 2019-004839-23: Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Recruiting
1/2
366
Europe, US, RoW
Emavusertib, CA-4948, Venetoclax
Curis, Inc., Curis, Inc
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
04/26
04/26
GEMINI II, NCT04718844: A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

Completed
1
44
Europe, RoW
SLN124, Placebo
Silence Therapeutics plc
Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome, Very-Low Risk Myelodysplastic Syndrome
05/23
05/23
NCT04174547: An European Platform for Translational Research in Myelodysplastic Syndromes

Recruiting
N/A
8670
Europe
Istituto Clinico Humanitas
Myelodysplastic Syndromes
09/21
09/22
GENOMED4ALL, NCT04889729: Improving MDS Classification and Prognosis by AI

Active, not recruiting
N/A
13284
Europe
Istituto Clinico Humanitas
Myelodysplastic Syndromes
12/22
12/24
NCT02192619: National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup

Recruiting
N/A
500
Europe
observational
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Newly-diagnosed APL (de Novo or Therapy-related), Relapsed APL
12/24
12/24
BoHemE, NCT02867085: Study Investigating the Interactions of Bone and Hematopoiesis in the Elderly

Completed
N/A
297
Europe
Observational
Technische Universität Dresden
Myelodysplastic Syndromes
08/24
08/24
Alakel, Nael
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
RECOVER, NCT05200754: Trial With or Without Infusion of SARS-CoV-2 Antibody Containing Plasma in High-Risk Patients With COVID-19

Recruiting
2
174
Europe
Convalescent/Vaccine-boosted Plasma (CP/PVP)
Carsten Müller-Tidow, German Federal Ministry of Education and Research, Institut für Klinische Transfusionsmedizin und Zelltherapie Heidelberg gGmbH
SARS-CoV-2 Infection
04/22
06/22
INITIAL-1, NCT03460522 / 2016-004836-39: Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL

Recruiting
2
65
Europe
Inotuzumab ozogamicin
Nicola Goekbuget, Pfizer Pharma GmbH
Precursor Cell Lymphoblastic Leukemia
06/25
12/25
GMALL-BLIVEN, NCT05182385: Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Recruiting
1/2
39
Europe
Blinatumomab, blincyto, Venetoclax, Venclyxto
Goethe University, University Hospital Schleswig-Holstein
ALL, Recurrent, Adult
06/25
12/25
Sockel, Katja
NCT05237713: Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients

Terminated
2
10
Europe
Canakinumab Injection, Ilaris(R)
University of Leipzig, Novartis Pharmaceuticals
Anemia, Myelodysplastic Syndromes
02/24
02/24
NCT06377462: Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection

Recruiting
N/A
500
Europe
Technische Universität Dresden, Bristol-Myers Squibb, University Hospital Munich
VEXAS Syndrome
12/29
12/30
PRO-RED, NCT05582902: Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients

Recruiting
N/A
60
Europe
University of Leipzig, Deutsche Krebshilfe e.V., Bonn (Germany)
MDS, MDS/MPN
03/25
03/25

Download Options